| 000 | 01527 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250511185039.0 | ||
| 264 | 0 | _c19930119 | |
| 008 | 199301s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/BF00685547 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKemena, A | |
| 245 | 0 | 0 |
_aInhibition of fludarabine metabolism by arabinosylcytosine during therapy. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _c1992 |
||
| 300 |
_a193-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aArabinonucleotides _xpharmacokinetics |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aDeoxycytidine Kinase _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aGandhi, V | |
| 700 | 1 | _aShewach, D S | |
| 700 | 1 | _aKeating, M | |
| 700 | 1 | _aPlunkett, W | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 31 _gno. 3 _gp. 193-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF00685547 _zAvailable from publisher's website |
| 999 |
_c1470643 _d1470643 |
||